Budesonide

Flexhaler is asthma maintenance from age 6; Respules is maintenance in children 12 months to 8 years. Neither treats acute bronchospasm. Selected 32 mcg nasal spray temporarily relieves hay-fever / upper-respiratory-allergy nasal symptoms from age 6; it is not for the common cold.

Selected 3 mg delayed-release capsules treat mild to moderate active Crohn’s disease of the ileum / ascending colon from age 8, with a weight restriction for pediatric dosing, and maintain adult remission for up to 3 months. Uceris oral tablets induce adult mild to moderate UC remission; rectal foam treats distal UC extending up to 40 cm from the anal verge. Eohilia treats EoE for 12 weeks from age 11. Tarpeyo reduces kidney-function loss in adults with primary IgA nephropathy at progression risk.

The reviewed single-agent forms have separate doses, release sites, durations and product instructions. Budesonide / formoterol combinations, other capsule products, off-label swallowed nebulizer mixtures and sinus-irrigation preparations are outside this profile. No universal steroid-equivalent substitution or disease-treatment selection algorithm is asserted.

Flexhaler: prime before first use, inhale deeply and forcefully, and rinse / spit after dosing. Respules: selected age 12 months to 8 years; 0.25 mg once daily may be considered for symptomatic children not responding to nonsteroidal therapy. Use a compressed-air jet nebulizer with suitable mask / mouthpiece, not an ultrasonic device; administer separately from other nebulized drugs. Gently shake the ampule and use promptly. Rinse afterward and follow mask / device cleaning instructions.

Selected 32 mcg spray: age 12 or older, two sprays per nostril once daily, reducing to one when improved. Age 6 to under 12, one per nostril once daily with adult supervision; if not improved, may increase to two, then reduce when controlled. Below 6 do not use. Shake well each time; prime / reprime per insert. Stop and consult if not improved after 2 weeks; discuss child use beyond 2 months / year. Do not double a missed dose.

Selected 3 mg Crohn’s capsules may be opened onto one tablespoon of soft, nonhot applesauce; swallow all within 30 minutes without chewing / crushing granules, then a glass of cool water. Do not save the mixture. This permission does not apply to Uceris tablets or Tarpeyo capsules. For foam empty bowels, warm / shake canister vigorously 10–15 seconds and follow its applicator instructions; evening use immediately before bedtime, trying to retain until morning. Avoid flame / smoking and pause before colonoscopy bowel preparation with clinical guidance.

Selected Crohn’s capsules: consider 3 mg once daily in adults with Child-Pugh B; avoid C, with no adjustment for A. Eohilia: same dose in A / B, monitor B, not recommended in C. Tarpeyo: monitor B and avoid C. Uceris tablet / foam: monitor moderate / severe disease and consider stopping for excess steroid effects; foam needs no change in A. Inhaled products require hepatic monitoring without a numerical adjustment table. Do not apply one hepatic rule or a universal prednisone taper to every form.

Flexhaler: primary treatment of status asthmaticus / acute episodes needing intensive measures, and severe milk-protein or component allergy. Respules: acute intensive-care asthma use and budesonide / ingredient allergy. Selected oral capsules, Uceris tablet / foam and Tarpeyo: budesonide or ingredient hypersensitivity; Eohilia §4 lists budesonide hypersensitivity. OTC nasal spray: do not use below 6 or with prior ingredient allergy. Formal allergy criteria do not erase the other product-specific avoidance instructions.

The selected eight single-agent budesonide labels have no boxed warning. Their adrenal, infection, growth, ocular and route-specific hazards still require prevention and monitoring.

Inhaled products report respiratory / ear infections, nasal or throat symptoms, GI symptoms and candidiasis. Oral Crohn’s / UC products report headache, GI symptoms, fatigue and steroid-related effects. Foam reports low cortisol, adrenal insufficiency and nausea. Eohilia reports respiratory infection, mucosal Candida, headache, gastroenteritis, throat irritation and erosive esophagitis. Tarpeyo reports edema, hypertension, muscle spasms, acne, headache and weight gain. Nasal warning symptoms include nosebleeds; rates are product- and study-specific.

Oral Crohn’s capsules, Eohilia and rectal foam advise avoiding CYP3A4 inhibitors; Tarpeyo specifies potent inhibitors. Examples include ketoconazole, itraconazole, ritonavir and clarithromycin-class strong inhibition; check the exact agent / product. Uceris oral tablets call for close monitoring and consideration of stopping the tablet or inhibitor. Oral products warn against grapefruit juice. Inhaled labels advise caution with strong inhibitors rather than a universal numerical dose reduction.

Uceris tablet coating is pH-dependent: PPIs, H2 blockers or antacids may alter release / uptake. Tarpeyo has not been evaluated with PPIs and its label discusses potential pH-dependent effects. These findings cannot be transferred to every budesonide form; selected capsule / Eohilia PK studies do not establish a universal acid-suppressant contraindication.

Review all oral, inhaled, nasal, skin and injected steroids to assess cumulative adverse effects and withdrawal risk. Respules should be nebulized separately because mixing effects are inadequately assessed. OTC nasal labeling asks about other steroid treatment. Steroid transfer and vaccine / infection decisions need the product’s actual clinical plan; no blanket equivalence or mixing rule is supplied.

Inhaled pregnancy studies have not shown increased congenital abnormalities; uncontrolled asthma also carries pregnancy risk. Oral / rectal evidence is limited and wording varies by product; in-utero corticosteroid exposure can cause neonatal hypoadrenalism. Budesonide enters milk after inhalation; oral / rectal lactation studies are limited, so individualize benefit / risk. Tarpeyo specifically recommends infant linear-growth monitoring with chronic maternal use. OTC nasal use requires a health-professional discussion during pregnancy or breastfeeding.

Flexhaler starts at 6; Respules at 12 months through 8 years; nasal at 6; selected Crohn’s treatment at 8 with weight above 25 kg; Eohilia at 11. Pediatric UC tablet / foam, Tarpeyo and Crohn’s maintenance efficacy / safety are unestablished. Monitor child growth and use exact pediatric dose ceilings. Older adults need cautious individual review for liver function, bone / ocular risks and interacting drugs; age alone does not create a shared dose adjustment.

Budesonide is primarily hepatically metabolized; reduced liver function may increase systemic exposure. Follow the differing Child-Pugh rules in Dosage. Renal metabolites are largely inactive; selected labels do not provide one universal renal-dose table. Tarpeyo’s kidney-disease indication does not authorize other capsules for IgA nephropathy, nor establish a generic dialysis regimen for all forms.

Budesonide acts at glucocorticoid receptors with strong glucocorticoid and weak mineralocorticoid effects, influencing inflammatory cells / mediators. Precise benefit mechanisms remain incompletely defined. Tarpeyo’s label describes ileal immune-cell effects but says the relative local versus systemic contribution to efficacy is unestablished; low systemic availability must not be equated with no systemic action.

Budesonide undergoes extensive CYP3A4 first-pass metabolism; metabolites have little glucocorticoid activity and are excreted in urine / feces. Delivered lung, nasal, gut, rectal and esophageal exposures differ. Example label estimates include Eohilia half-life about 3.3 hours and Tarpeyo 5.0–6.8 hours; inhaled studies differ again. These are studied product contexts, not interchangeable duration-of-action or renal-dose rules.

Follow asthma symptoms / rescue use and lung function; review worsening control promptly. Monitor children’s growth and assess Candida, infection, adrenal effects, BP / glucose, bone and ocular risks as appropriate. Oral and rectal regimens need response / relapse review and hepatic-risk assessment; Eohilia new esophageal symptoms may need endoscopy, while Tarpeyo requires kidney-disease response follow-up. Nasal symptoms persisting after 2 weeks need reassessment. No common cortisol threshold, visit interval or efficacy target applies to every formulation.

Verify route, strength and delivery instructions at each prescription. Inhaled products are maintenance: keep the prescribed rescue treatment available and rinse / spit after dosing. Shake nasal / Respules / Eohilia as directed. Do not crush release products; only the selected Crohn’s capsule permits its applesauce method. Follow Eohilia’s 30 minute wait and Tarpeyo’s meal timing / final taper. Report infection exposure, severe allergy, immediate wheeze, visual changes or steroid-withdrawal symptoms; do not independently stop prolonged systemic treatment.

Seek medical / Poison Control advice for overdose or wrong-route use. Prolonged excessive exposure can cause systemic steroid effects and adrenal suppression; treatment / withdrawal is clinical, not a home antidote or automatic taper. Do not inject nebulizer suspension, swallow rectal foam or replace an esophageal product with a nebulizer mixture.

Product

Pulmicort Flexhaler 180 mcg / dose

Route

Oral inhalation dry powder; prescription

Appearance

White inhaler body / cover; brown turning grip

Example package

Selected device · NDC 85612-011-01

Selected forms: Flexhaler 90 / 180 mcg per dose; Respules 0.25 / 0.5 / 1 mg in 2 mL; nasal 32 mcg per spray; Crohn’s delayed-release 3 mg capsules (grey / pink, ENTOCORT EC 3 mg imprint); Uceris 9 mg ER tablet (white round MX9); Uceris rectal foam 2 mg per metered dose; Eohilia 2 mg / 10 mL packet; Tarpeyo 4 mg delayed-release capsule (white CAL10 4MG). Similar names or milligram totals do not make these equivalent.

Flexhaler: dry 20–25°C with cover secured; discard when empty. Respules: upright 20–25°C, protect light, do not freeze; unused ampules in opened foil last 2 weeks when protected, and opened ampules are used promptly. Nasal: 20–25°C, protect light, do not freeze.

Crohn’s capsules: 25°C, excursions 15–30°C, tightly closed. Uceris tablet: same range, protect light / moisture. Tarpeyo: 20–25°C, excursions 15–30°C, tight and protected from moisture. Eohilia: refrigerated or room temperature 2–25°C, excursions up to 30°C; do not freeze.

Rectal foam: 20–25°C, excursions 15–30°C; do not refrigerate, puncture / incinerate or expose above 49°C. Avoid flame / smoking during and immediately after administration. Do not transfer one product’s refrigeration or opened-foil discard rule to another.